Intercept Pharma (ICPT) Posts Narrwer-than-Expected Q3 Loss

Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.10), $0.65 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $445 thousand versus the consensus estimate of $420 thousand.

As of September 30, 2015, Intercept had cash, cash equivalents and investment securities available for sale of approximately $695.7 million, compared to $732.2 million as of June 30, 2015.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M